Preclinical Evidence for Phage Therapy to Treat Mycobacterial Infections: A Narrative Review

Résumé fourni par la source

Phage therapy shows promise for treating mycobacterial infections, though clinical trial data on efficacy are still needed. We review preclinical studies assessing the efficacy and safety of phage therapy in mycobacterial diseases, focusing on in vitro , ex vivo , and in vivo models to inform clinical trial design. Most studies addressed Mycobacterium tuberculosis (M. tb) , with phage D29 commonly used. Of all studies reporting activity, 91% (20/22) reported reduced mycobacterial counts. Some phages (4/7 assessed) also demonstrated activity against intracellular mycobacteria. Animal models (seven studies) showed efficacy and safety of four phages assessed, in infection models for M. tb , Mycobacterium ulcerans , Mycobacterium avium , and Mycobacterium abscessus , respectively. Substantial variability in results could be explained by experimental designs used. To advance clinical trials, we recommend standardized preclinical experiments on phage susceptibility, intracellular activity, and sampling from infection sites. This preclinical evidence supports further exploration of phage therapy for mycobacterial infections in clinical trials.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.